http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 01 Jul 2025 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html <p>SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab.</p> <p>Ho’ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be http://www.streetinsider.com/Press+Releases/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html Tue, 01 Jul 2025 08:00:00 -0400 A.50204699 A.50205019 O.00168799 O.00706867 ONCT http://www.streetinsider.com/Press+Releases/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html <p>SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab.</p> <p>Ho’ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be http://www.streetinsider.com/Press+Releases/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html Tue, 01 Jul 2025 08:00:00 -0400 A.50204699 A.50205019 O.00168799 O.00706867 ONCT http://www.streetinsider.com/Press+Releases/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html <p>SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab.</p> <p>Ho’ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be http://www.streetinsider.com/Press+Releases/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html Tue, 01 Jul 2025 08:00:00 -0400 A.50204699 A.50205019 O.00168799 O.00706867 ONCT http://www.streetinsider.com/Press+Releases/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html <p>SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab.</p> <p>Ho’ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be http://www.streetinsider.com/Press+Releases/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html Tue, 01 Jul 2025 08:00:00 -0400 A.50204699 A.50205019 O.00168799 O.00706867 ONCT http://www.streetinsider.com/Press+Releases/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html <p>SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab.</p> <p>Ho’ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be http://www.streetinsider.com/Press+Releases/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html Tue, 01 Jul 2025 08:00:00 -0400 A.50204699 A.50205019 O.00168799 O.00706867 ONCT http://www.streetinsider.com/Globe+Newswire/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html <p>SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab.</p> <p>Ho’ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be http://www.streetinsider.com/Globe+Newswire/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html Tue, 01 Jul 2025 08:00:00 -0400 A.50204699 A.50205019 O.00168799 O.00706867 ONCT http://www.streetinsider.com/Globe+Newswire/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html <p>SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab.</p> <p>Ho’ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be http://www.streetinsider.com/Globe+Newswire/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html Tue, 01 Jul 2025 08:00:00 -0400 A.50204699 A.50205019 O.00168799 O.00706867 ONCT http://www.streetinsider.com/Globe+Newswire/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html <p>SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab.</p> <p>Ho’ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be http://www.streetinsider.com/Globe+Newswire/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html Tue, 01 Jul 2025 08:00:00 -0400 A.50204699 A.50205019 O.00168799 O.00706867 ONCT http://www.streetinsider.com/Globe+Newswire/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html <p>SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab.</p> <p>Ho’ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be http://www.streetinsider.com/Globe+Newswire/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html Tue, 01 Jul 2025 08:00:00 -0400 A.50204699 A.50205019 O.00168799 O.00706867 ONCT http://www.streetinsider.com/Globe+Newswire/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html <p>SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab.</p> <p>Ho’ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be http://www.streetinsider.com/Globe+Newswire/Oncternal+Therapeutics+Announces+the+Sale+of+Select+Development+Programs+and+the+Wind-Down+of+its+Operations/25001506.html Tue, 01 Jul 2025 08:00:00 -0400 A.50204699 A.50205019 O.00168799 O.00706867 ONCT http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Press+Releases/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html <p> VANCOUVER &amp; DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. </p><p> "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of http://www.streetinsider.com/Business+Wire/Alpha+Cognition+Strengthens+Its+Leadership+Team+with+Appointment+of+Robert+Wills+to+Board+of+Directors+and+Announces+Departure+of+Existing+Director+John+Havens/24623695.html Thu, 10 Apr 2025 08:30:00 -0400 A.50113751 ACOG CBAY MIST O.00169771 O.00638032 O.07505859 O.40625266 ONCT